Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: Gerald Walls who wrote (498)	10/23/1998 2:32:00 PM
From: Marty	Respond to of 857

They don't ever claim to "cure" a disease, all they ever say is that it is used to "treat" the disease. "Treat" is the operative word. I started out by saying I appreciate that the testimonials don't prove anything and I know that the FDA doesn't work "that way" as you say. I do say again, however, that these testimonials are not nothing and I HOPE the FDA takes this type of thing into consideration.

To: Gerald Walls who wrote (498)	10/23/1998 3:31:00 PM
From: Gerald Underwood	Read Replies (1) \| Respond to of 857

Gerald, I am not too sure that any of us can delineate just exactly what the decision making process of the FDA is composed of. However, we all know that a picture is worth a thousand words, and human interaction with subjective descriptions may well fill in some very important blanks that are not produced by cut and dry scientific measurements. What test can they give you to determine your "feel good" state. Much more so when in all likelyhood, these particular subjective feelings and experiences are consistently backed up by measurable clinical data so laboriously obtained from prolonged trials. Aren't Double blind placebo studies designed to take just these factors into account. Nobody is entirely taking anyone's word for anything in clinical trials, therefore insuring objective results as is possible. Regards, Gerry

To: Gerald Walls who wrote (498)	10/24/1998 1:22:00 PM
From: Cavalry	Respond to of 857

if asenio doesnt come out hard on monday re letter of infraction we all will know he has covered and moved on leaving his followers to crash and burn...window of opp for asassinio, orphan status fiasco was his last pr and his greatest blunder to date...except for messing with doc carter that was catastrophic error. Hemispherx Complying with FDA Request PR Newswire - October 23, 1998 18:14 NEW YORK, Oct. 23 /PRNewswire/ -- Hemispherx Biopharma (Amex: HEB) said today that on October 22, 1998, it was one of three pharmaceutical companies receiving a "Notice of Infraction" from the Food and Drug Administration (FDA). The other companies were Pfizer and Bristol Myers. Hemispherx said that it is fully complying with the FDA request not to undertake any communications about investigational new drugs in a "promotional context." The context of the company's recent communications had been to correct misinformation disseminated in the past few weeks by stock market short sellers. This misinformation included statements about the potential efficacy and safety of Ampligen in the treatment of Chronic Fatigue Syndrome, which could have been of concern to patients currently undergoing treatment under clinical protocols, their physicians, patient advocacy groups and investors. The misinformation spread by the short sellers was not based on any information released by the FDA or any other government body and contradicted the results of clinical trials as reported in peer review medical journals and at scientific conferences. Hemispherx said that its program of clinical trials and applications for approval in both the U.S. and Europe are proceeding on schedule. Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. SOURCE Hemispherx Biopharma /CONTACT: William A. Carter, M.D., CEO and Chairman of Hemispherx Biopharma, 215-988-0080; or Media: William J. Jenks, 212-232-2222, Fax: 212-232-3232 or Investor Relations: Sharon Will, 212-572-0762 or Fax: 212-572-0764, both for Hemispherx/ /Web site: hemispherx.com (HEB) -------------------------------------------------------------------------------- HEB %MTC V%PRN P%PRN